ClinicalTrials.Veeva

Menu
C

Cedars-Sinai Medical Center | Smidt Heart Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
BI 1015550
Atezolizumab
Vedolizumab
Belzutifan
Lenalidomide
prednisone
Bevacizumab
Tacrolimus
cyclophosphamide

Parent organization

This site is a part of Cedars-Sinai Medical Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

69 of 123 total trials

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy (ACES-EMB)

This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance...

Not yet enrolling
Heart Transplant Failure and Rejection
Diagnostic Test: The Prospera™ Test

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitum...

Active, not recruiting
Gastric Cancer
Ovarian Cancer
Drug: CUE-102

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study...

Active, not recruiting
ALS
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: ABBV-CLS-7262

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting
Kidney Cancer
RCC
Drug: MK-3795
Drug: Nivolumab

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only
Hypertension
Familial Primary Pulmonary Hypertension
Drug: Ralinepag

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combina...

Active, not recruiting
Metastatic Colorectal Cancer
Drug: Inavolisib
Drug: FOLFIRI

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod...

Enrolling
Colitis, Ulcerative
Drug: Ozanimod

This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph...

Enrolling
KRAS G12V
NRAS G12D
Drug: ELI-002 7P

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin
Locations recently updated

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a...

Enrolling
Renal Cell Carcinoma
Drug: HC-7366
Drug: Belzutifan
Locations recently updated

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants w...

Active, not recruiting
Breast Neoplasms
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Drug: Bevacizumab

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untr...

Enrolling
Non-small Cell Lung Cancer
Drug: SBRT
Drug: Alectinib

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting
Breast Cancer
Drug: 5-Fluorouracil
Drug: Cyclophosphamide

This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e.,...

Enrolling
Colorectal Carcinoma
KRAS Mutation-Related Tumors
Drug: ompenaclid
Drug: FOLFOX regimen

RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety...

Active, not recruiting
Hypertension
Vascular Diseases
Device: Sham Procedure
Device: The Paradise® Renal Denervation Ultrasound System

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moder...

Enrolling
Ulcerative Colitis
Drug: Tofacitinib
Drug: Vedolizumab

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling
Primary Sclerosing Cholangitis
Drug: Placebo Matched to Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 120 mg

Trial sponsors

Cedars-Sinai Medical Center logo
Abbott logo
Cytokinetics logo
Takeda logo
Edwards Lifesciences logo
Lilly logo
Roche logo
Abiomed logo
Amgen logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems